Michael Grau

2.7k total citations
30 papers, 1.3k citations indexed

About

Michael Grau is a scholar working on Immunology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael Grau has authored 30 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 12 papers in Molecular Biology and 12 papers in Pathology and Forensic Medicine. Recurrent topics in Michael Grau's work include Lymphoma Diagnosis and Treatment (12 papers), NF-κB Signaling Pathways (9 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Michael Grau is often cited by papers focused on Lymphoma Diagnosis and Treatment (12 papers), NF-κB Signaling Pathways (9 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Michael Grau collaborates with scholars based in Germany, Switzerland and United States. Michael Grau's co-authors include Georg Lenz, Peter Lenz, Bernd Dörken, Stephan Hailfinger, Hendrik Nogai, Daniel Krappmann, Michelle Vincendeau, Matthias Pfeifer, Margot Thome and Daniel Nagel and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Genes & Development.

In The Last Decade

Michael Grau

30 papers receiving 1.3k citations

Peers

Countries citing papers authored by Michael Grau

Since Specialization

Citations

This map shows the geographic impact of Michael Grau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Grau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Grau more than expected).

Fields of papers citing papers by Michael Grau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Grau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Grau. The network helps show where Michael Grau may publish in the future.

Co-authorship network of co-authors of Michael Grau

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Grau. A scholar is included among the top collaborators of Michael Grau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Grau. Michael Grau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identification of Tensin-3 as a MALT1 substrate that controls B cell adhesion and lymphoma dissemination 2023 ·Proceedings of the National Academy of Sciences ·Mélanie Juilland, (unknown), (unknown), (unknown), (unknown), Léonardo Scarpellino, Tabea Erdmann, Michael Grau, Georg Lenz, Sanjiv A. Luther, Margot Thome	2
2	BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis 2023 ·Blood ·Anja Schmitt, Melanie Grimm, (unknown), (unknown), (unknown), (unknown), Caroline Schönfeld, (unknown), (unknown), Kerstin Menck, Annalen Bleckmann, Claudia Lengerke, Frank Rosenbauer, Michael Grau, Mattia Zampieri, Klaus Schulze‐Osthoff, Pavel Klener, (unknown), Georg Lenz, Stephan Hailfinger	38
3	mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma 2022 ·Leukemia ·Wendan Xu, Philipp Berning, Tabea Erdmann, Michael Grau, (unknown), Myroslav Zapukhlyak, (unknown), Corinna Kosnopfel, Peter Lenz, Michael Grondine, Brandon S. Willis, James T. Lynch, Pavel Klener, Stephan Hailfinger, Simon T. Barry, Georg Lenz	18
4	Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial 2022 ·Leukemia ·Ciara L. Freeman, (unknown), Ling Jin, Sriram Balasubramanian, Aixiang Jiang, Wendan Xu, Michael Grau, Myroslav Zapukhlyak, Merrill Boyle, Brendan P. Hodkinson, Michael Schäffer, Christopher Enny, Sanjay Deshpande, Steven Sun, Jessica Vermeulen, Ryan D. Morin, David W. Scott, Georg Lenz	3
5	Identifying plastics with photoluminescence spectroscopy and machine learning 2022 ·Scientific Reports ·(unknown), (unknown), (unknown), Michael Grau, Martín Koch, Peter Lenz	11
6	Lymphocyte access to lymphoma is impaired by high endothelial venule regression 2021 ·Cell Reports ·Lutz Menzel, (unknown), (unknown), Vedran Franke, Michael Grau, (unknown), Anja E. Hauser, Volker Siffrin, Marc Bajénoff, (unknown), Altuna Akalin, Georg Lenz, Gerald Willimsky, Uta E. Höpken, Armin Rehm	12
7	Lymphoma Angiogenesis Is Orchestrated by Noncanonical Signaling Pathways 2020 ·Cancer Research ·(unknown), Lutz Menzel, Michael Grau, Anne-Clémence Vion, Ioannis Anagnostopoulos, Myroslav Zapukhlyak, Kerstin Gerlach, Thomas Kammertöns, Thomas Hehlgans, (unknown), Georg Lenz, Holger Gerhardt, Uta E. Höpken, Armin Rehm	13
8	The transcription factor C/EBPβ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions 2020 ·Proceedings of the National Academy of Sciences ·(unknown), Michael Grau, Lutz Menzel, (unknown), Myroslav Zapukhlyak, Achim Leutz, Martin Janz, Georg Lenz, Armin Rehm, Uta E. Höpken	15
9	Targeting chronic NFAT activation with calcineurin inhibitors in diffuse large B-cell lymphoma 2019 ·Blood ·Philip Bucher, Tabea Erdmann, (unknown), Wendan Xu, Anja Schmitt, (unknown), Myroslav Zapukhlyak, Caroline Schönfeld, Edgar Serfling, Daniela Kramer, Michael Grau, Pavel Klener, Claudia Lengerke, Klaus Schulze‐Osthoff, Georg Lenz, Stephan Hailfinger	27
10	MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells 2019 ·Cell Reports ·Torben Gehring, Tabea Erdmann, (unknown), Carina Graß, Andrew Flatley, Thomas J. O’Neill, (unknown), Isabel Meininger, Özge Karayel, (unknown), Michael Grau, Hisaaki Shinohara, Katja Lammens, Regina Feederle, Stefanie M. Hauck, Georg Lenz, Daniel Krappmann	22
11	Dissection of gene expression datasets into clinically relevant interaction signatures via high-dimensional correlation maximization 2019 ·Nature Communications ·Michael Grau, Georg Lenz, Peter Lenz	3
12	Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma 2018 ·Translational Oncology ·Torsten Keßler, (unknown), Caroline Brand, Michael Grau, Linus Angenendt, (unknown), (unknown), L. H. Schmidt, Georg Gosheger, Jendrik Hardes, Dimosthenis Andreou, (unknown), Georg Lenz, Eva Wardelmann, Rolf M. Mesters, Christian Schwöppe, Wolfgang E. Berdel, Wolfgang Hartmann, Christoph Schliemann	19
13	Splenic Marginal Zone Granulocytes Acquire an Accentuated Neutrophil B-Cell Helper Phenotype in Chronic Lymphocytic Leukemia 2016 ·Cancer Research ·(unknown), (unknown), Michael Grau, Kerstin Gerlach, Ralph Kettritz, Jörg Westermann, Ioannis Anagnostopoulos, Peter Lenz, Georg Lenz, Uta E. Höpken, Armin Rehm	31
14	Oncogenic CARMA1 couples NF-κB and β-catenin signaling in diffuse large B-cell lymphomas 2016 ·Oncogene ·(unknown), Michelle Vincendeau, Tabea Erdmann, Thomas Seeholzer, Michael Grau, Jelena R. Linnemann, Jürgen Ruland, Christina Scheel, Peter Lenz, German Ott, Georg Lenz, Stefanie M. Hauck, Daniel Krappmann	39
15	Access to Follicular Dendritic Cells Is a Pivotal Step in Murine Chronic Lymphocytic Leukemia B-cell Activation and Proliferation 2014 ·Cancer Discovery ·(unknown), (unknown), Michael Grau, (unknown), Ioannis Anagnostopoulos, Kerstin Gerlach, Raluca Niesner, Zoltán Cseresnyés, Anja E. Hauser, Peter Lenz, Thomas Hehlgans, Robert Brink, Jörg Westermann, Bernd Dörken, Martin Lipp, Georg Lenz, Armin Rehm, Uta E. Höpken	56
16	Pharmacologic Inhibition of MALT1 Protease by Phenothiazines as a Therapeutic Approach for the Treatment of Aggressive ABC-DLBCL 2012 ·Cancer Cell ·Daniel Nagel, Stefani Spranger, Michelle Vincendeau, Michael Grau, Silke Raffegerst, (unknown), (unknown), Martin Neuenschwander, Jens Peter von Kries, Kamyar Hadian, Bernd Dörken, Peter Lenz, Georg Lenz, Dolores J. Schendel, Daniel Krappmann	186
17	MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma 2012 ·Leukemia ·(unknown), Michael Grau, Cory Mavis, Stephan Hailfinger, Annette Wolf, Hannelore Madle, G. Michael Deeb, Bernd Dörken, Margot Thome, Peter Lenz, Stefan Dirnhofer, Francisco J. Hernandez‐Ilizaliturri, Alexandar Tzankov, Georg Lenz	78
18	Malt1-dependent RelB cleavage promotes canonical NF-κB activation in lymphocytes and lymphoma cell lines 2011 ·Proceedings of the National Academy of Sciences ·Stephan Hailfinger, Hendrik Nogai, Christiane Pelzer, Maike Jaworski, (unknown), (unknown), (unknown), Chantal Décaillet, Michael Grau, Bernd Dörken, Peter Lenz, Georg Lenz, Margot Thome	179
19	The Use of Microarray Technologies in Mantle Cell Lymphoma 2011 ·Seminars in Hematology ·Boris A. Ratsch, Michael Grau, Bernd Dörken, Peter Lenz, Georg Lenz	2
20	Opposing roles of NF-κB in anti-cancer treatment outcome unveiled by cross-species investigations 2011 ·Genes & Development ·Jing Hua, Julia Kase, Jan R. Dörr, Maja Milanovic, Dido Lenze, Michael Grau, (unknown), (unknown), Maurice Reimann, Peter Lenz, Michael Hummel, Bernd Dörken, Georg Lenz, Claus Scheidereit, Clemens A. Schmitt, Soyoung Lee	72

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact